Antipsychotic-induced tardive dyskinesia: update on epidemiology and management. Issue 3 (May 2019)

• Record Type: Journal Article
• Authors: Widschwendter, Christian G.; Hofer, Alex
• Is Part Of: Current opinion in psychiatry. Volume 32:Issue 3(2019:May)
• Publication Date: 2019-05
• Subjects: antipsychotics -- incidence -- management -- prevalence -- tardive dyskinesia; Psychiatry -- Periodicals; 616.89005
• DOI: 10.1097/YCO.0000000000000491
• Languages: English
• ISSNs: 0951-7367

Abstract

Abstract : Purpose of review: To provide an update on the frequency of antipsychotic-induced tardive dyskinesia and its management in patients with schizophrenia spectrum disorders in studies published since the last systematic review in 2008. Recent findings: Recent data about antipsychotic-induced tardive dyskinesia in patients with schizophrenia underscore the superiority of newer generation antipsychotics (21%) over first-generation antipsychotics (30%) with respect to prevalence and incidence rates. Regarding recently tested management strategies, the new vesicular monoamine transporter 2 inhibitors valbenazine and deutetrabenazine have been found to be effective and may be considered as first-line pharmacotherapy for tardive dyskinesia. Owing to quality issues of randomized controlled trials and/or small sample sizes, limited and conflicting evidence remains for most treatment strategies. Summary: The reviewed literature reveals lower prevalence rates of antipsychotic-induced tardive dyskinesia in patients treated with newer generation compared with first-generation antipsychotics. The evidence of vesicular monoamine transporter 2 inhibitors as a first-line therapy for tardive dyskinesia is well supported by several controlled clinical trials.